TABLE 1.
Clinical characteristics of core binding factor acute myeloid leukemia and non core binding factor myeloid leukemia.
| Non‐CBF‐AML (n = 74) | CBF‐AML (n = 75) | p | |
|---|---|---|---|
| ELN risk classification | |||
| Favorable | 50 (67.5%) | 57 (76%) | 0.121 |
| Intermediate | 17 (22.9%) | 8 (10.6%) | |
| High | 7 (9.4%) | 10 (13.3%) | |
| Sex | |||
| Male | 47 (63.5%) | 47 (62.6%) | 0.915 |
| Female | 27 (36.4%) | 28 (37.3%) | |
| Age (years) | 44 (16–75) | 38 (14–77) | 0.162 |
| Specific mutations | |||
| CEBPA | 27 (36.4%) | 1 (1.3%) | |
| NPM1 | 33 (44.5%) | 2 (2.6%) | |
| FLT3 | 14 (18.9%) | 10 (13.3%) | |
| TP53 | 1 (1.3%) | 1 (1.3%) | |
| IDH | 5 (6.7%) | 2 (2.6%) | |
| Induction therapy | |||
| IA | 39 (52.7%) | 30 (40%) | 0.120 |
| Others | 35 (47.2%) | 45 (60%) | |
| Consolidation therapy | |||
| Chemotherapy | 16 (21.6%) | 27 (36%) | 0.072 |
| Auto‐HSCT | 5 (6.7%) | 10 (13.3%) | |
| Allo‐HSCT | 52 (70.2%) | 37 (49.3%) | |
| UCBT | 1 (1.3%) | 1 (1.3%) | |
| ECOG | 1 (0–4) | 1 (0–4) | 0.270 |
| Type of AML | 0.067 | ||
| De novo | 65 (87.8%) | 72 (96%) | |
| Secondary | 9 (12.1%) | 3 (4%) | |
| Cytogenetic categories | |||
| Autosomal abnormalities | 5 (6.7%) | 12 (16%) | 0.129 |
| Sex chromosome abnormalities | 3 (4.1%) | 11 (14.7%) | 0.031 |
| Complex karyotype | 0 | 10 (13.3%) | 0.001 |
| WBC (×109/L) | 12.29 (0.67–311.28) | 12.79 (0.95–391.60) | 0.522 |
| HGB (g/L) | 88.5 (35–158) | 80 (35–139) | 0.086 |
| PLT (×109/L) | 38 (5–430) | 25 (5–424) | 0.018 |
| BM blasts (%) | 61.5 (14–99) | 52.5 (20–96.5) | 0.434 |
| Extramedullary involvement | 3 (4%) | 1 (1.3%) | 0.603 |
| CNS leukemia | 4 (5.4%) | 8 (10.6%) | 0.370 |
Abbreviations: Allo‐HSCT, allogeneic stem cell transplantation; auto‐HSCT, autologous stem cell transplantation; BM, bone marrow; CNS, central nervous system; ELN, European Leukemia Net; HGB, hemoglobin; Mut, mutation; Others induction therapy contains DA, VA, MA, HA, HAE, HAA, CAG, DCAG, AZA‐HAG, Priming; PLT, palatelete; UCBT, umbilical cord blood transplantation; WBC, white blood cell.